Business Context and Reporting Period
This Form 8-K filing by Syndax Pharmaceuticals, Inc. reports on the results of the Annual Meeting of Stockholders held on May 23, 2018. The company is an emerging growth company incorporated in Delaware.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting results.
Material Changes and Voting Results
The following proposals were submitted to a vote of security holders:
- Proposal 1: Election of Directors
- Henry Chen: Elected with 10,313,293 votes For, 1,800,907 Against, and 5,278,332 Broker Non-Votes.
- Luke Evnin, Ph.D.: Elected with 10,077,732 votes For, 2,036,778 Against, and 5,278,332 Broker Non-Votes.
- Both nominees were elected to serve a three-year term until the 2021 Annual Meeting.
- Proposal 2: Ratification of Independent Auditor
- Stockholders ratified the selection of Deloitte & Touche LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2018.
- Votes: 17,360,374 For, 21,049 Against, and 13,946 Abstain.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items.
Investor Verification Checklist
- Verify the definitive proxy statement filed on April 10, 2018, for detailed descriptions of the proposals.
- Confirm the total number of shares outstanding to calculate the percentage of votes cast for each proposal.
- Review the company's most recent 10-K or 10-Q for financial performance data, as this 8-K contains no financial metrics.